The $17.00 cash consideration represents a 22% premium to the pre-announcement closing price on March 3, 2026, and a 10% premium to VWAP since that date. The CVR provides asymmetric upside if ampreloxetine is successfully monetized, but has no guaranteed value. Monitor the shareholder vote and HSR clearance timeline. The deal is not subject to a financing condition, reducing execution risk. The stock should trade near the cash consideration minus deal risk and time value of money.
TBPH drugs
TBPH drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $17.06entry
- T+1 · 5mo ago −0.35%α −1.13% · $17.00
- T+5 · 4mo ago −0.35%α −1.74% · $17.00
- T+20 · 4mo ago −1.17%α −0.89% · $16.86
- T+60 · 8w ago −0.18%α −4.56% · $17.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theravance Biopharma (TBPH) entered into a definitive merger agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash plus one contingent value right (CVR) per share. The CVR entitles holders to 80% of net proceeds from any future monetization of ampreloxetine over ten years, plus a potential $50M milestone payment and 10% royalties on net sales. The all-cash deal values TBPH at approximately $929M equity value and is expected to close in H2 2026, subject to shareholder and regulatory approvals. The filing also includes employee communications (Item 7.01) and a press release (Item 8.01).
Key Financial Metrics
Key Facts
- Shareholders to receive $17.00 per share in cash plus one CVR per share
- CVR provides 80% of net proceeds from any ampreloxetine license/divestiture within 10 years post-close
- CVR also includes a $50M aggregate milestone payment upon first commercial sale in a Major Market
- CVR includes 10% royalty on net sales of ampreloxetine during the Royalty Term
- Equity value of the cash consideration is approximately $929 million
- Transaction expected to close in the second half of 2026
- Closing conditions include shareholder approval (two-thirds vote), HSR clearance, and no material adverse effect
- Parent has secured debt financing from OMERS Life Sciences; no financing condition to close
- Termination fee of $32.515M payable by either party in specified circumstances
- Company's Strategic Review Committee and Board unanimously approved the transaction
Financial Impact
Shareholders receive $17.00 per share in cash (~$929M equity value) plus CVR with potential additional value from ampreloxetine monetization (80% of net proceeds, $50M milestone, 10% royalties).
Risk Factors
- Shareholder approval may not be obtained
- Regulatory approvals (HSR) may be delayed or denied
- CVR may yield zero value if ampreloxetine is not monetized or commercialized
- Competing acquisition proposal could emerge and disrupt the deal
- Integration risks post-close could affect YUPELRI franchise performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078453 |
| Document: tm2619064d1_8k.htm | 0001104659-26-078453 |
| Document: tm2619064d1_ex99-3.htm | 0001104659-26-078453 |
| Document: tm2619064d1_ex99-1.htm | 0001104659-26-078453 |
| Document: tm2619064d1_ex99-2.htm | 0001104659-26-078453 |
| Document: 0001104659-26-078453-index-headers.html | 0001104659-26-078453 |
| Document: 0001104659-26-078453-index.html | 0001104659-26-078453 |
| Document: 0001104659-26-078453.txt | 0001104659-26-078453 |
Track record
12 reports on TBPH
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
- Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
- Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
- Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
- Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
- Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Viewing Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers